Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan)

Aug 5

Written By Kimberly Hicks

Kimberly Hicks

Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!

Congratulations to Dr. Pushkal Garg on his appointment as EVP, Chief Research & Development Officer at Alnylam Pharmaceuticals.